DAIICHI SANKYO COMPANY, LIMITED Logo

DAIICHI SANKYO COMPANY, LIMITED

A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.

4568 | T

Overview

Corporate Details

ISIN(s):
JP3475350009
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daiichi Sankyo is a global pharmaceutical company focused on the research, development, and delivery of innovative medical solutions. The company's core business revolves around creating novel therapies, with a primary strategic focus on oncology. It is a leader in the science of antibody-drug conjugates (ADCs), a class of targeted cancer drugs. Beyond oncology, its portfolio and development pipeline include treatments for cardiovascular diseases and other specialty areas. The company manufactures and markets a range of prescription medicines, vaccines, and over-the-counter healthcare products, aiming to contribute to the enrichment of quality of life for patients worldwide by creating new standards of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 05:22
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 05:19
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 321.7 KB
2025-10-10 02:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-10-03 04:15
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 130.8 KB
2025-09-05 03:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-08-07 05:49
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-17 02:04
Registration Form
発行登録書(株券、社債券等)
Japanese 24.8 KB
2025-07-09 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-24 06:02
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-24 05:36
Post-Annual General Meeting Information
臨時報告書
Japanese 25.7 KB
2025-06-23 08:40
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-23 07:44
Share Issue/Capital Change
臨時報告書
Japanese 31.3 KB
2025-06-20 07:20
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-20 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 07:19
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 3.0 MB

Automate Your Workflow. Get a real-time feed of all DAIICHI SANKYO COMPANY, LIMITED filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAIICHI SANKYO COMPANY, LIMITED

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAIICHI SANKYO COMPANY, LIMITED via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.